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Background: Onychomycosis is a common nail pathology which has proven to be a treatment challenge to
healthcare professionals. Antifungal drugs have been the mainstay of therapy for many years. Recently, laser
technologies have been introduced as a treatment for onychomycosis avoiding the disadvantages of systemic and
topical drug therapies, offering a rapid treatment for an often persistent nail condition. The purpose of this study
was to review published evidence regarding the effectiveness of laser technologies in the treatment of
onychomycosis.
Methods: The primary question for this review was “what evidence is there for the use of lasers in the treatment of
onychomycosis”? A systematic literature search of published papers indexed on Pubmed and Web of Science® was
undertaken in June 2014 for original, published research. The primary outcome measures for efficacy were
mycological cure and clearance of the affected nail (clinical cure).
Results: This review returned a total of twelve eligible published studies evaluating the use of lasers in the
treatment of onychomycosis. Two were randomised controlled trials, four were comparative design studies (with no
placebo/control groups) and the remainder were case series. The level of evidence was generally low level
reflecting predominantly small sample size and lack of control groups. The results from studies were conflicting and
follow up periods for patients in studies were generally short. Many studies excluded patients with severe or
dystrophic onychomycosis.
Conclusions: The evidence pertaining to the effectiveness of laser treatment of onychomycosis is limited and of
poor methodological quality. Future studies using a randomised controlled trial designs with larger study
populations and clear procedures are required to permit a full evaluation of this emerging technology.
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Lasers have been a part of podiatric practice for many
years. Papers discussing their potential uses in clinical
practice started to appear in the 1980s, particularly fo-
cussing on the high powered carbon dioxide (CO2) sys-
tems available at that time [1-3]. Much of this work
discussed their ablative abilities in nail matrixectomies
and their early potential for onychomycosis following
total nail ablation [1] and by nail fenestration to improve
topical drug delivery [4] but generally their use remained
in the hands of a few specialist practitioners, mainly
in the USA. This continued for several years with newerCorrespondence: ib@soton.ac.uk
Faculty of Health Sciences, B67, Highfield Campus, University of
Southampton, Southampton SO17 1BJ, UK
© 2014 Bristow; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.systems being slowly introduced such as the pulsed dye
laser, which has been explored as a treatment for plantar
warts with varying levels of success [5-8]. The expense
of these early systems was prohibitive for everyday prac-
tice and so their use was limited.
In 2009, for the first time a surgical laser system was
advertised in the UK Podiatry magazine Podiatry Now
indicated for the treatment of onychomycosis. Shortly
afterwards, a letter was published suggesting that this
was “possibly the most radical development in the treat-
ment of onychomycosis our profession has ever seen”
[9]. Some concerns were expressed at the unproven effi-
cacy of these new devices and the investment costs in-
volved [10]. In addition, despite it now being nearly five
years since their first introduction into practice littleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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demonstrating their effectiveness despite their introduc-
tion into UK clinics, evident through internet searches,
offering this treatment modality. Similar concerns have
been expressed in the dermatological fields with laser
systems for onychomycosis being “praised uncritically
and promoted at high prices” [11].
Lasers systems are attractive for the practitioner and
public alike for a number of reasons. Oral drug regimens
have showed effectiveness in many studies and remain
the most studied intervention for this condition. How-
ever, debate is always raised about the safety of oral
drugs, despite many years’ experience with these agents
and safety reporting [12,13]. Antifungal drugs, like many
others, are contra-indicated in patients with active or
chronic liver disease [14] and are sometimes declined by
patients seeking alternatives to oral medication - often
to avoid potential for side-effects. Topical agents too, are
considered by many to be a protracted and frequently
ineffective intervention as patient compliance over the
treatment period can be an issue. Lasers are often mar-
keted as a means of improving a practice’s income and
are seen as an investment which can pay for itself in a
short period of time. Lasers also capture the imagination
of the public as a safe, effective quick fix for a range of
clinical conditions.
The proposed mechanism of action of lasers in the
treatment of onychomycosis remains unclear. However,
laser systems in near infra-red spectrum (780 nm –
3000 nm wavelength), which are commonly used in ony-
chomycosis, exert their effect by direct heating of the
target tissues [15]. Moreover, by using a pulsed beam in-
stead of continuous beam, these lasers can deliver a “se-
lective photothermolysis” [16] – delivering of a short
burst of laser light energy into the target tissue causing a
rapid elevation in temperature into the defined target
area. Sufficient intervals between pulses can allow for
tissue relaxation and cooling to occur, causing very little
collateral damage to surrounding structures. In the la-
boratory, eradication of the common dermatophyte Tri-
chophyton rubrum has been demonstrated using pulsed
laser technology [17]. Studies on fungal nail clippings
have demonstrated this to have a direct thermal killing
effect on fungal mycelia when treatment temperatures
exceed 50° centigrade [18].
Lasers for nail disease have been approved in the United
States by the Food and Drug Administration (FDA). To
date, devices have been approved only on their ability to
temporary clear nail growth in onychomycotic nails [19],
and not on definitive curative data. Consequently evaluation
of their capabilities remains a necessity to inform practi-
tioners of their effectiveness in the longer term. A literature
review published in 2013 [20] which, in part, discussed laser
technology in onychomycosis concluded that evidence waslacking due to small scale studies and poor design however,
this was not systematic. Consequently, the author has
undertaken a systematic literature review to assess the
published results and evidence of effectiveness to date.
Review
Methods
This study was compiled adopting the “Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines” [21]. Any original study, published
in a peer reviewed journal, which examined the use of a
laser technology in the treatment of onychomycosis (in
more than a single case) was considered for inclusion. The
primary outcome measure was efficacy, only including
studies which employed microbiological or histological
procedures to establish an initial diagnosis of the condi-
tion, and subsequently measured the outcome either by a
repeated microbiological/histological assessment or mea-
sured changes in physical nail clearance of discolouration
following treatment. Studies which did not follow this pro-
cedure were excluded, as were those which stated they ex-
clusively studied fingernail onychomycosis.
Search strategy
An electronic database search was undertaken using
PubMed (US National Library of Health Database [June
2014]) and Web of Science® (June 2014) to identify papers
which met the initial inclusion criteria. Searches were
standardized using a combination of the keywords “ony-
chomycosis”, “tinea unguium”, “laser”, “nail”, “rubrum”.
No date limits were set, but as a relatively new modality,
papers over six years old were unlikely. The initial search
yielded a total of 268 potential papers. All abstracts were
reviewed to remove duplicates and to remove papers
which did not meet the inclusion criteria. Papers which
met the inclusion parameters were then read in full by the
author. Only papers written in English, with full study de-
tails available were included in the final suite of papers.
This exercise was repeated twice by the author to improve
the reliability of the search and prevent eligible papers be-
ing missed or excluded (Figure 1).
Review process
Following the selection process, remaining papers were
evaluated for their level of evidence using two systems as
adopted by Matricciani et al. [13]. Firstly, papers were
graded using the National Health and Medical Research
Council (NHMRC) Hierarchy of Evidence [22] scale (see
Additional file 1) and subsequently the American Occupa-
tional Therapy Association (AOTA) Evidence based litera-
ture Review Project, as adapted by Trombly and Ma [23]
(see Additional file 2) as a means to identify threats to val-
idity within the included studies. This system allowed for
the objective assessment of published research, graded on
Figure 1 Flow Diagram of search strategy (conducted
June 2014).
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and external validity.
Results
Initial evaluation demonstrated a variety in study proce-
dures which precluded detailed statistical comparisons
and so a structured review of the papers was undertaken
to examine and compare methods and results. In total,
13 papers were initially deemed eligible, however one
paper [24] was an extension of an earlier published
paper already included in the review [25] so was
excluded.
All of the 12 remaining papers were published in the last
four years [25-36]. Reflecting the novelty of this technol-
ogy, four studies stated they were “preliminary” or pilot
studies [26-28,31]. Two papers adopted a randomised
controlled trial methodology [25,29], three were compara-
tive designs [27,35,36] whilst the remainder were case
series [26,28,30-34].
The majority of studies (10 papers) investigated the
1064 nm neodymium: yittrium-aluminum-garnet laser
system (Nd:YAG) (long and short pulse types) either as a
sole intervention [26-29,31,33,34,36], as a Q switched
1064 nm/532 nm wavelengths system [30], or as a com-
parison against a 1319 nm and broadband wavelength de-
vice [35]. One study employed an 870/930 nm dual band
system [25] and another investigated the use of an ablative
carbon dioxide laser as a means to fractionate nails to en-
hance the penetration of topical anti-fungal agents [32].Three papers stated that fingernails had been included in
the study [28,33,36] but none exclusively, so were in-
cluded. A tabulated summary of all included studies is
given in Table 1 along with an assessment of the level of
evidence and validity measures in Table 2.
In a randomized controlled trial by Landsman and
colleagues [25], 36 patients with proven onychomycosis
were randomly allocated to either a laser treatment
using a continuous wave Noveon™ 870 nm/930 nm laser
or control sham device. Following a detailed protocol, all
patients were treated at day 1, 14, 42 and day 60. Blinded
assessors reviewed photographic evidence at various
stages to assess and record any changes. At 6 months,
34 patients (37 toes: 26 treated and 11 controls) were
eligible for analysis. Visually, only 2 treated nails had
completely or markedly improved (versus 2 controls)
whilst slight to moderate improvement was seen in 18
treated nails versus 3 control nails and 6 treated nails
were unchanged along with 6 control nails. The study
was declared as being funded exclusively by a laser
manufacturer and employees of the company were listed
as co-authors of the paper.
In another randomized controlled trial, Hollmig et al.
[29] enrolled 27 patients with culture or PAS stain con-
firmed onychomycosis to receive either 2 treatments
with a 1064 nm Nd:YAG laser (two weeks apart) or no
treatment. At three months all patients affected nails
were re-assessed by culture and measured nail clearance
with an additional measurement for the treated group at
month 12. The results showed that at 3 months, 33% of
the laser treated group achieved a negative culture ver-
sus 20% in the control group and had more proximal
nail clearance at this time, although there was no statis-
tically significant difference between the two groups. At
month 12, there was no difference in measured nail
clearance between the treated and control group. The
authors suggested that the laser may only have a tem-
porary effect in onychomycosis.
Hochman [28] undertook a study of 8 patients with
culture or PAS stain confirmed onychomycosis and
treated them using a LightPod NeoTM 1064 nm short
pulsed Nd:YAG laser (Nd:YAG laser). After 2–3 treat-
ments, three weeks apart, they were re-assessed at an
unspecified follow-up time of at least 4 months. The
author reported a 7 out of 8 patients showing visual
improvement (although this was not quantified) and
negative fungal cultures. However, in this study, no de-
scription was given about the level of nail involvement
at the beginning of the study to ascertain the extent of
the disease. In addition, patients were encouraged to use
daily antifungal agents during treatment applied to the
nail. Small numbers were used in this study and the fol-
low up time was not formalized ranging from 16 to over
24 weeks.
Table 1 Summary of studies included in the review









Case Series 10 (18) 1064 nm Nd:YAG (short Pulse). 1 treatment. Culture 24 weeks Decrease in area of nail visually affected measured with the





10 (20) 1064 nm (long v. short pulse) on each hallux 2
treatments over 4 weeks (side by side
comparison).
Histology 36 weeks Decrease in area of nail visually affected measured with the
Onychomycosis Severity Index (OSI). Negative histology & cultures.
Hochman
[28]




24 weeks Negative fungal cultures.
Hollmig
et al. [29]




52 weeks Negative cultures and measured clearance at 3 months for all
subjects, and repeated clearance measurement at 12 months for
those treated with laser.
Kalokasidis
et al. [30]
Case Series 131 (unknown) 1064 nm/532 Q switched Nd:YAG. 2
treatments, 30 days apart.
Microscopy &
Culture
12 weeks Decrease in area of nail visually affected measured with the
Onychomycosis Severity Index (OSI) and negative cultures.
Kimura
et al. [31]




Improvements in nail turbidity score and, negative culture if nail
was 100% improved in turbidity score.
Landsman
et al. [25]
RCT 36 (37) 870 nm/930 nm laser or sham control device. 4
treatments over 60 days.
Culture or
PAS




Case Series 24 (unknown) CO2 laser. 3 treatments at 4 weeks plus topical
treatment.
Microscopy 24 weeks Decrease in affected nail surface area and negative microscopy.
Moon
et al. [33]




24 weeks Decrease in affected nail surface area and negative microscopy.
Noguichi
et al. [34]










21 (21) 1064 nm ND:YAG v. 1319 nm v. Broadband
light. 4 treatments at one week apart.





33 (154) (18)* 1064 nm Nd:YAG (long pulse) Either 4 OR 8
treatments - one week apart.
Microscopy &
Culture


























Threats to internal validity External
validity
Threats to external validity
Carney et al. [26] IV C 2 20% attrition b Only DLSO mycosis of the hallux included
Unblinded assessment
Hees et al. [37] III-3 C 1 b Only T Rubrum mycosis included
Hochman [28] IV C 2 Antifungal cream used post intervention. b Type of onychomycosis treated not classified
Variable follow up periods




IV A 3 Short follow up period OSI results not fully reported b Mainly mild/DLSO mycosis treated
No control group
Kimura et al. [31] III-3 A 3 Variable no. of treatments (1–3) b Mainly DLSO mycosis treated
Turbidity scoring not validated
Landsman et al.
[25]
II B 2 Smaller control than treatment group b Majority cases mild to moderate mycosis
Industry sponsorship/authorship
Lim et al. [32] IV B 2 Blinding procedures for nail grading not clear. b Majority cases mild to moderate mycosis
Not stated how many finger v. toe nails included
Moon et al. [33] IV C 2 Limited details on nail scoring system validation b Mainly (DLSO) included
Noguichi et al. [34] IV C 2 Limited detail on independence of nail score
assessment
b Severe nail disease or thick nails excluded - only mild/DLSO cases
included
Waibel et al. [35] III-3 B 2 No control/placebo group b Types of mycosis included not reported
Limited detail on how nail clearance assessed and
reported
Zhang et al. [36] III-3 B 3 No control/placebo group b Types of mycosis included not reported
Limited detail on how nail clearance assessed
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of 13 subjects (37 toe nails) and investigated the effective-
ness of the Cutera™ Nd:YAG short pulse laser in the treat-
ment of patients with dystrophic nails, microscopically
confirmed as onychomycosis. Nails were treated two or
three times 4–8 weeks apart. The main outcomes assessed
were evidence of clear nail growth (using a nail turbidity
score) and a negative fungal clipping. The majority of pa-
tients presented with distal lateral sub-ungual onychomy-
cosis (n = 9). At the end of the study (week 16) 19 nails
(51%) showed complete clearance (clear nail and negative
microscopy) with 30 nails (81%) showing from moderate
to complete improvement. The authors declared that the
equipment for the study had been loaned from the manu-
facturers but did not state if the results were independent
of the company.
In a more recent study by Moon et al. [38] 43 toenails
and 12 finger nails with culture and PAS stain confirmed
onychomycosis underwent 5 treatments using a Nd:YAG
1064 nm laser system at four week intervals. At 24 weeks
from the start of the study nails were assessed for sur-
face clearance and negative cultures. One month after
the final treatment 30 of the 43 nails had negative mi-
croscopy. Four nails achieved a complete cure (negative
microscopy and complete visual clearance in the nail
plate). Eight patients were reported to have achieved
>80% nail clearance and 31 nails (50-80% clearance of
nail surface area).
Using the Pinpointe™ Laser System (1064 nm Nd:
YAG) with a long pulse duration, Zhang and colleagues
[36] randomly assigned into two treatment groups, 33
microscopically and fungal culture positive patients (154
nails) with onychomycosis to either 8 treatments at one
week intervals (group 1) or 4 treatments at one week in-
tervals (group 2). Patients were followed up for 24 weeks.
There was no significant difference in the mycological
cure rates which were 51% (group 1) and 53% (group 2)
at 24 weeks. Interestingly, they reported recurrence on
the disease in 10 nails (5 patients) within a 2–4 month
period after the study, suggesting that the laser had only
temporarily inhibited growth and not destroyed the fun-
gus outright.
Waibel et al. [35] undertook a study using three types
of laser light (1064 nm, 1319 nm and broadband filtered
flash light) randomly assigning 21 patients to one of the
modalities. All patients had PAS confirmed disease and
had positive microscopy cultures. Each nail was treated
with 10 minutes of laser light and received four, weekly
treatments and were assessed at 1, 3 and 6 months. Tis-
sue temperature was also recorded in this study to sug-
gest what effect the laser was having on the treated area.
The authors reported improvement in the nail appear-
ance with “clearing” and a high satisfaction rate, with
only mild discomfort reported by patients. Althoughthese findings were not quantified, they reported 100%
negative cultures for the 1064 nm laser system and
Broadband light with one failure for the 1319 nm sys-
tem. The sample sizes for this study were small with 7
subjects in each arm. A measured temperature of 46 de-
grees centigrade was achieved for all treatments. Based
on the results the authors concluded that this was a le-
thal temperature which would achieve the desired
outcome.
In a larger study Kalokasidis et al. [30] treated 131 pa-
tients with microbiologically confirmed onychomycosis
using a Q-Clear™ Q-Switched Nd:YAG 1064 nm/532 nm
laser following nail reduction with a drill. Patients under-
went two treatments, 30 days apart, using both wave-
lengths each time and then were reviewed at two months.
The results demonstrated an impressively high cure rate,
assessed by microscopy and culture, of 95.4% in the study
group which is much higher than other studies have re-
ported. The data suggested that distal sub-ungual onycho-
mycosis and superficial white onychomycosis are very
amenable to this modality whilst lesser results were ob-
served in patients with severely dystrophic nails. As the
authors state the follow up time for assessment in this
study was very short as effective nail growth can take up
to 12–18 months to fully reveal the nail post-operatively.
Although the nail severity index was used initially to as-
sess nail involvement, subsequent score post-intervention
were not fully reported.
In a Japanese paper, Noguchi et al. [34] treated the hal-
lux nails of 12 mycological positive patients with a Gen-
tleYAG™ 1064 Nd:YAG laser. Nails with severe disease
were excluded (>75% surface area affected or >3 mm
plate thickness) so the treated group only presented with
distal lateral sub-ungual onychomycosis type. All
patients underwent the minimum of 3 treatments at 4-
week intervals with nail turbidity (clearance) assessed at
3 and 6 months. Mycological cure rates were not
assessed in this study, only visible improvement mea-
sured through changes in affected nail surface area. Only
three patients showed a significant improvement (25%)
with two showing improvement (16.7%) and six patients
(50%) showing no improvement or worsening. The
authors concluded from their results that this procedure
was no better than topical nail lacquer therapy based on
the cure rates achieved.
Carney et al. [26] as part of a range of experiments
undertook a study of 10 patients (18 nails) with onycho-
mycosis. In the clinical part of their study, they selected
10 patients with mycologically proven onychomycosis
and undertook a treatment using a single 1064 nm Nd:
YAG system. This study included rigorous assessment
of the nails before and after using the OSI measure as
well as the mycological evidence to assess outcomes
with a 24 week programme. They could not show
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rates using this laser system and regime.
Hees et al. [27] reported a ten patient pilot study also
employing a comparative design of the two types of
1064 Nd:YAG systems (short pulse versus long pulse).
Patients included had all grades of onychomycosis
caused by T rubrum with mycological confirmation in
both halluces and underwent a left hallux/right hallux
comparison of the two laser systems with a two treat-
ment regime spaced four weeks apart to both nails. Nail
changes were independently assessed by two observers
using standardised photography and the OSI [39] with a
nine-month follow up. Despite mycological clearance
rates of around 65% in this small sample, the OSI grad-
ing changed very little for participants – improving
slightly within the first six months and then reversing
slightly at the end of the nine month study. In conclu-
sion, although 65% had mycologically been cured, clinic-
ally only 4 cases had shown visible improvement.
Only one study evaluated the carbon dioxide ablative
laser (CO2) in the treatment of onychomycosis [32]. The
function of laser therapy in this study was to render the
nail more permeable to facilitate penetration of concur-
rent topical amorolfine to affected nails which was then
evaluated. After three treatments at 4 week intervals, 24
patients with confirmed onychomycosis were assessed at
six months for negative cultures and improvements in
clear nail growth. At this time, 50% of patients had nega-
tive culture and had 100% nail clearance whilst only 2
patients (8%) showed no response. As the authors point
out, mild forms of onychomycosis such as superficial
white onychomycosis responded best whilst no improve-
ment was seen in the totally dystrophic cases.
Discussion
This review of published papers has yielded 12 studies
investigating the use of lasers in the treatment of ony-
chomycosis. Sample sizes in all studies were generally
small ranging from 8 [28] to 131 patients [30], with six
studies having 20 or fewer patients [26-28,31,33,34].
Only one paper offered a detailed design and protocol
with a control (sham) intervention [24].
On review of the data available, a number of issues arise.
Firstly, looking at early results it is clear that there is no
consensus on laser effectiveness with conflicting study re-
sults being evident. This, in part, is due to the heterogeneity
of the study designs at many stages. Although all papers
reviewed onychomycosis in adults, selection criteria showed
variation. Most focussed on older adult samples reflecting
the fact that onychomycosis is a disease are more prevalent
in this age group [40] however, definitive diagnosis for in-
clusion relied on a single test result in some studies
[25-29,31,32] or a combination of tests such as Periodic
Acid-Schiff (PAS) stain, microscopy, positive fungal cultureor polymerase Chain Reaction (PCR) in others
[30,33,35,36,41]. The variability of these tests have been in-
vestigated. Weinberg et al. [42] examined 94 nail samples
and suggested the sensitivities of KOH as 80%, PAS 92%
and culture 59%. More recently developed PCR techniques
are considered to the new standard technique in detecting
dermatophyte presence [43] with detection rates similar to
PAS staining technique [44].
The research to date highlights the difficulty in what
constitutes an effective “cure” in onychomycosis and how
it is measured. Mycological cure is defined as clearance of
the nail based on negative mycological test findings such
as microscopy, culture and PAS staining, however this can
be complicated when an individual may show mixed re-
sults when exposed to a range of different mycological
tests. Moreover, a negative culture result may not equate
to improvement in the nail appearance (known as “clinical
cure”). A “complete cure” is a combination of mycological
and clinical cure – effectively the nail is free from fungus
and visually, returns to normal.
Visual appearance in some studies was based on pa-
tient satisfaction levels [36] whilst others measured clear
nail emergence [25,31,34] or formalised the changes in
the amount of nail plate surface affected and its associ-
ated changes. The OSI [39] was a commonly used in-
strument [26,27,30] and categorised nails based on the
amount of nail surface area affected. Other studies made
no formal visual assessment [28,35]. As previous papers
have discussed [45,46] assessing what constitutes a cure
is difficult, requiring further work to provide a meaning-
ful outcome for the clinician and the patient.
Another factor for consideration is the duration
of the study. Most studies ran between 12–24 weeks
[25,26,28,30-36], with one recent study continuing to
36 weeks [27] and one to 12 months [29]. In fully assessing
the effectiveness of laser therapy, it is perhaps important to
consider nail growth rate. In adults, toenails grow around
1.0 mm/month however in the elderly, the rate of nail
growth decreases by approximately 0.5% per year between
25 to 100 years of age [47]. In addition, it has been shown
that nails infected with dermatophytes grow at a slower rate
than uninfected nail plates, proportional to amount of nail
affected [48]. Consequently, for a full nail growth to occur
post-intervention, a longer time period of up to 24 months
maybe a more suitable way to assess effectiveness. The
Hees et al. study [27], which suggested deterioration in the
visual appearance of the some nails, had a longer follow up
than most studies whilst Zhang and colleagues [36] re-
ported rapid relapse in five patients (a total of 10 nails).
Moreover, Hollmig et al. [29] noted that although modest
improvement in nail clearance was observed in their laser
treated group at 3 months compared to the control group,
this was not sustained at 12 months, suggesting only a tem-
porary effect.
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duration the risks of relapse or reinfection potentially
increase. Relapse is defined as a recurrence of the nail
infection, resulting from insufficient clearing of the ori-
ginal infection from the nail, whereas reinfection is a
new infection occurring in a nail that has been previ-
ously cleared of all infection. It has been shown that re-
infection is a common occurrence in onychomycosis
[49,50] probably occurring as the patient re-acquires
dermatophytic fomites from previously worn footwear
and hosiery. In such studies, the use of preventative
measures such as shoe and sock disinfection or topical
nail lacquers and antifungal creams may be a useful
addition following completion of laser treatment to
counteract the effect of reinfection. Only two studies in
this review employed the use of a topical antifungal ap-
plied to the skin or nails after treatment deliberately to
reduce reinfection [25,28].
Other issues worthy of discussion, include nail thick-
ness and severity of the infection. Increased nail thick-
ness in any type of treatment for onychomycosis acts as
a potential barrier. Noguichi et al. [34] measured nail
thickness and excluded those with a nail thickness of
greater than 3 mm suggesting that the 1064 nm laser
can only penetrate down to this depth. Kalokasidis et al.
[30] employed the use of a nail drill prior to treatment
in their study, Hees et al. stated that they did not in
their study deliberately seek to drill nails prior to ther-
apy [27]. All other studies did not state, either way, if
nail reduction was employed [25,26,28,29,31-33,35,36].
The use of nail drilling prior to antifungal drug use has
been shown to be effective in improving cure rates
[51,52] but its effect in laser treatment remains a point
to be tested.
The type of onychomycosis is a factor which may the
affect the outcome of treatment. The four main types are
distal lateral sub-ungual onychomycosis (DLSO), superficial
white onychomycosis (SWO), proximal white sub-ungual
onychomycosis (PWSO) and total dystrophic onychomyco-
sis (TDO). The extent of the nail infection will potentially
have a bearing on the treatment success. The DLSO and
PWSO varieties showed in some studies being more re-
sponsive to treatment possibly owing to their mild to mod-
erate presentation when compared to the more severe
proximal PSO and TDO varieties. Clear documentation of
the profile of type of onychomycosis presenting in study co-
horts would permit a clearer judgement on the lasers effect-
iveness. Four studies [28,29,35,36] did not profile the
onychomycosis at presentation whilst two only included
DLSO or SWO [26,34]. The remaining five studies included
all types [25,27,30-32], however in four of these studies, the
vast majority were DLSO cases [25,30-32].
Setting up and running clinical trials for new laser
technologies can be costly and time consuming. To thatend, sponsorship from industry may not be entirely ob-
jectionable in researching new devices [11] but it is an
important factor to be considered in judging the validity
of any study. Of the 11 included studies, only one paper
made no declaration of competing interests [36] whilst
four papers declared competing interests ranging from
loan of equipment [31], to individual author involve-
ments with associated companies [26,35], through to
full sponsorship and involvement in study design and
authorship in one study [25].
This paper set out to systematically review current
evidence in the treatment of onychomycosis employing
laser technologies. However, there are potential limita-
tions to this work. Firstly, whilst this review includes pa-
pers published and indexed on two large databases
(Web of Science® and PubMed), it must be stated that
these libraries are not exhaustive and therefore cannot
cover all relevant publications. As an emerging modal-
ity, searches of the internet reveal much more literature
in the form of documents, papers and posters but it is
difficult to objectively ascertain their origins, peer re-
view status or whether any conflicts of interest exist.
Therefore, only recognised databases have been used for
this review. In addition, only studies written in English
and which are readily accessible through normal
methods have been included.Conclusion
In the last five years, papers have been published investi-
gating the application of lasers in treating onychomycosis.
Twelve studies were identified and included in this review.
Most of the published data to date is reported at a low
level of evidence predominantly case series involving small
numbers of patients and with only two small randomized
controlled studies. Outcomes appeared to be measured on
visual nail clearance measurements following treatment,
mycological evidence of cure or both. Studies with longer
follow up periods suggest nail infection relapse occurring
in those treated with laser which warrants further investi-
gation. However, overall conflicting results are shown in
this review of studies with no clear evidence of efficacy.
There were no studies published comparing laser with
more traditional therapies in the treatment of onychomy-
cosis. Comparative studies are required with improved
design such as longer follow up periods, classification of
the type of nail infection and control interventions to truly
assess the effectiveness of laser devices in the management
of onychomycosis.Additional files
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